Majem M, Goldman JW, John T, Grohe C, et al. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer who underwent Adjuvant Osimertinib in the phase III ADAURA trial. Clin Cancer Res 2022 Jan 10. pii: 1078-0432.CCR-21-3530.
PMID: 35012927